ConforMIS, Inc. CFMS is set to report first-quarter 2019 results on May 1, after market closes.
The company delivered an earnings surprise of 20% in the last reported quarter. Its earnings topped the consensus mark in three of the last four quarters, the average beat being 15.3%.
Let’s take a look at how things are shaping up prior to this announcement.
The company has been seeing solid revenue growth on robust performance by its product lines as well as steady royalties.
Strong iTotal PS sales have been driving the company’s top line globally. Within the United States, the company’s revenues are gaining from the rollout of its ConforMIS Hip System.
ConforMIS, Inc. Price and EPS Surprise
ConforMIS, Inc. Price and EPS Surprise | ConforMIS, Inc. Quote
Based on these factors, the company registered 7% year-over-year growth in product revenues in the last-reported quarter. The company expects this trend to continue in the first quarter of 2019.
The company is expected to register promising royalty revenues, just like in the preceding quarter, following the win of its patent license litigation with Smith & Nephew last September.
In the first quarter, ConforMIS is expected to rake in strong revenues on several commercial activities like broadening of its customer base, increasing agent representatives, direct-to-consumer initiatives and enhanced medical education offerings. These are expected to reflect in the first-quarter 2019 revenue performance.
The Zacks Consensus Estimate for first-quarter revenues is pegged at $20.1 million, indicating 2.3% year-over-year growth.
What Our Quantitative Model Suggests:
The proven Zacks model shows that a company with a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chances of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
ConforMIS has a Zacks Rank #2 and an Earnings ESP of 0.00%, a combination that does not hint at earnings beat.
Stocks Worth a Look
Here are a few medical stocks worth considering from the same space as these have the right mix of elements to exceed expectations this reporting cycle.
Evolus, Inc. EOLS has an Earnings ESP of +24.39% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
NanoString Technologies Inc. NSTG has an Earnings ESP of +3.08% and a Zacks Rank #3.
Aurora Cannabis, Inc. ACB has an Earnings ESP of +73.33% and a Zacks Rank #3.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors. Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ConforMIS, Inc. (CFMS) : Free Stock Analysis Report
NanoString Technologies, Inc. (NSTG) : Free Stock Analysis Report
Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report
Evolus, Inc. (EOLS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research